Effects of oxytocin on adreno-medullary catecholamine synthesis, uptake and storage in rats exposed to chronic isolation stress.

PURPOSE/AIM: The adreno-medullar system represents one of the main systems involved in the response to stressful events. The neuropeptide oxytocin, is highly sensitive to the social environment, and regulates autonomic function. Adreno-medullary activity is dependent on the synthesis of catecholamine, its reuptake, release, degradation and vesicular transport. A direct influence of oxytocin on catecholamine synthesizing enzyme and transports in animals exposed to chronic social isolation stress has not been studied yet. MATERIALS AND METHODS: In the present study, we examined the effect of chronic oxytocin treatment on the level of plasma catecholamine and its content, mRNA and protein levels of tyrosine hydroxylase (TH), noradrenaline transporter (NET) as well as vesicular monoamine transporter 2 (VMAT2) in the adrenal medulla of socially isolated rats. RESULTS: Our results show that, by the end of 12 weeks, social isolation did not produce any significant changes in catecholamine content but increased plasma catecholamine level and synthesis in the adrenal medulla. Oxytocin treatment had no further effect either on catecholamine synthesis or content in socially stressed animals whereas a significant elevation of plasma norepinephrine and epinephrine were reduced. On the other hand, chronic isolation caused a significant increase in VMAT2 and decrease in NET protein levels. Oxytocin treatment brought about an increase in protein levels of NET and its return to the levels of control group. Besides, it further increases VMAT2 protein levels in the adrenal medulla of individually housed rats. CONCLUSION: The present results show that peripheral oxytocin treatment enhances catecholamine uptake and storage in the adrenal medulla of chronically isolated animals.

Dopamine drives Drosophila sechellia adaptation to its toxic host.

Many insect species are host-obligate specialists. The evolutionary mechanism driving the adaptation of a species to a toxic host is, however, intriguing. We analyzed the tight association of Drosophila sechellia to its sole host, the fruit of Morinda citrifolia, which is toxic to other members of the melanogaster species group. Molecular polymorphisms in the dopamine regulatory protein Catsup cause infertility in D. sechellia due to maternal arrest of oogenesis. In its natural host, the fruit compensates for the impaired maternal dopamine metabolism with the precursor l-DOPA, resuming oogenesis and stimulating egg production. l-DOPA present in morinda additionally increases the size of D. sechellia eggs, what in turn enhances early fitness. We argue that the need of l-DOPA for successful reproduction has driven D. sechellia to become an M. citrifolia obligate specialist. This study illustrates how an insect's dopaminergic system can sustain ecological adaptations by modulating ontogenesis and development.

Anti-inflammatory and anti-apoptotic effects of (RS)-glucoraphanin bioactivated with myrosinase in murine sub-acute and acute MPTP-induced Parkinson's disease.

This study was focused on the possible neuroprotective role of (RS)-glucoraphanin, bioactivated with myrosinase enzyme (bioactive RS-GRA), in an experimental mouse model of Parkinson's disease (PD). RS-GRA is one of the most important glucosinolates, a thiosaccharidic compound found in Brassicaceae, notably in Tuscan black kale seeds. RS-GRA was extracted by one-step anion exchange chromatography, further purified by gel-filtration and analyzed by HPLC. Following, pure RS-GRA was characterized by (1)H and (13)C NMR spectrometry and the purity was assayed by HPLC analysis of the desulfo-derivative according to the ISO 9167-1 method. The obtained purity has been of 99%. To evaluate the possible pharmacological efficacy of bioactive RS-GRA (administrated at the dose of 10mg/kg, ip +5µl/mouse myrosinase enzyme), C57BL/6 mice were used in two different sets of experiment (in order to evaluate the neuroprotective effects in different phases of the disease), according to an acute (2 injections·40mg/kg MPTP) and a sub-acute (5 injections·20mg/kg MPTP) model of PD. Behavioural test, body weight changes measures and immunohistochemical localization of the main PD markers were performed and post-hoc analysis has shown as bioactive RS-GRA is able to reduce dopamine transporter degradation, tyrosine hydroxylase expression, IL-1ß release, as well as the triggering of neuronal apoptotic death pathway (data about Bax/Bcl-2 balance and dendrite spines loss) and the generation of radicalic species by oxidative stress (results focused on nitrotyrosine, Nrf2 and GFAP immunolocalization). These effects have been correlated with the release of neurotrophic factors, such as GAP-43, NGF and BDNF, that, probably, play a supporting role in the neuroprotective action of bioactive RS-GRA. Moreover, after PD-induction mice treated with bioactive RS-GRA are appeared more in health than animals that did not received the treatment both for phenotypic behaviour and for general condition (movement coordination, presence of tremors, nutrition). Overall, our results suggest that bioactive RS-GRA can protect neurons against the neurotoxicity involved in PD via an anti-apoptotic/anti-inflammatory action.

Efecto de la exposición al pesticida rotenona sobre el desarrollo del sistema dopaminérgico nigro-estriatal en ratas / Developmental effects of rotenone exposure on the rat nigro-striatal dopaminergic system

Rotenone is a pesticide used in Mexico, despite the experimental evidence showing dopaminergic neurons degeneration induced by this compound, which may lead to a psychomotor impairment. However, the possible effects of rotenone on the offspring when they are indirectly exposed through their mothers are still unknown. In this study rotenone was administered to female rats during pregnancy and nursing, in order to assess its effects on the offspring's dopaminergic neurons in the substantia nigra, as well as on motor coordination at 30 or 60 postnatal days. Six groups of pregnant Wistar rats were used: an intact control group, a vehicle group injected with the rotenone solvent, and four groups injected subcutaneously with the following doses of rotenone: 0.2, 0.4, 0.6, and 1 mg/kg/day. In a parallel experiment, the offspring of other groups of dams treated with rotenone 1 mg/kg/day, or controls vehicle-treated, were used to evaluate motor coordination at 30 and 60 postnatal days. Rotenone treated dams showed a significant lower amount of dopaminergic neurons in the substantia nigra, but only with the 1 mg/kg dose. This effect was also observed in the offspring but at all doses of rotenone tested, either at 30 or 60 postnatal days. Furthermore, the offspring of rotenone exposed dams significantly increased the time in which they accomplished the motor coordination test, compared to the offspring of control dams. These data indicate that rotenone is able to damage the dopaminergic neurons of the offspring though their mothers. This effect requires lower rotenone doses than in adult rats. The reduced number of dopaminergic neurons at early stages of life enhances the risk of developing disorders related to the brains' dopaminergic system.

La rotenona es un pesticida utilizado en México a pesar de que se ha demostrado experimentalmente que produce una degeneración de las neuronas dopaminérgicas, y puede derivar en deterioro psicomotor. Sin embargo, no existen estudios de la exposición indirecta a rotenona a través de las madres en el efecto que produzca sobre su descendencia. Nosotros administramos rotenona a ratas durante la gestación y la lactancia para evaluar las alteraciones producidas sobre las neuronas dopaminérgicas y la coordinación motora de sus crías, a los 30 o 60 días posnatales. Para cuantificar las neuronas inmunorreactivas a tirosina hidroxilasa de la sustancia nigra, se inyectaron subcutáneamente seis grupos de hembras Wistar: intactas (control), con solvente de rotenona (vehículo) y cuatro grupos con rotenona en dosis: 0.2, 0.4, 0.6 y 1.0 mg/kg/día. En un experimento paralelo, las crías de otros grupos de hembras tratadas con rotenona 1 mg/kg/día o controles fueron evaluados en la prueba de coordinación motora a los 30 y 60 días posnatales. Las madres tratadas con 1 mg/kg de rotenona tuvieron menos neuronas dopaminérgicas en la sustancia nigra. Dicho efecto se observó también en las crías, pero con todas las dosis de rotenona utilizadas, tanto a los 30 como a los 60 días posnatales. Además, la exposición indirecta a rotenona aumentó significativamente el tiempo que requirieron las crías para ejecutar la prueba de coordinación motora. Estos datos indican que la rotenona es capaz de inducir daño en las neuronas dopaminérgicas de las crías cuando son expuestas a través de sus madres. Este efecto en las crías se observa con dosis menores de rotenona que en ratas adultas. Por lo tanto, los individuos indirectamente expuestos a rotenona podrían tener menos neuronas dopaminérgicas desde etapas tempranas de la vida, lo que aumenta el riesgo de desarrollar trastornos relacionados con el sistema dopaminérgico.